Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists seek perfect dose for life-saving drug in ICU's sickest patients

NCT ID NCT04868188

Summary

This study aimed to understand how a common antifungal drug, voriconazole, behaves in the bodies of critically ill patients. Researchers measured drug levels in 32 adults with severe COVID-19 or flu who were on a life support machine called ECMO and had a serious fungal infection. The goal was to gather information to help doctors give the most effective and safest dose to future patients in similar situations.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University Hospitals of Leicester

    Leicester, United Kingdom

Conditions

Explore the condition pages connected to this study.